

1 **Functional network analysis identifies multiple virulence and antibiotic resistance systems**  
2 **in *Stenotrophomonas maltophilia***

4 **Larina Pinto<sup>1</sup>, Rajesh P Shastry<sup>2</sup>, ShivaKiran Alva<sup>1</sup>, R. Shyama Prasad Rao<sup>1,3,\*</sup>, Sudeep D**  
5 **Ghate<sup>1,3,\*</sup>**

7 <sup>1</sup> Center for Bioinformatics, NITTE deemed to be University, Mangaluru 575018, India

8 <sup>2</sup> Division of Microbiology and Biotechnology, Yenepoya Research Centre, Yenepoya (Deemed  
9 to be University), University Road, Deralakatte, Mangalore-575018, India

10 <sup>3</sup> Central Research Laboratory, KS Hegde Medical Academy, NITTE deemed to be University,  
11 Mangaluru 575018, India

14 \*Corresponding authors

15 E-mail: sudeep1129@gmail.com

16 drrsprao@gmail.com

22 Running title: Virulence and AMR network in *S. maltophilia*.

23

24

25

26

27

28

29

30

31

32

33

34

35

36 **ABSTRACT**

37

38 *Stenotrophomonas maltophilia*, an emerging multidrug-resistant opportunistic bacterium in  
39 humans is of major concern for immunocompromised individuals for causing pneumonia and  
40 bloodborne infections. This bacterial pathogen is associated with a considerable fatality/case  
41 ratio, with up to 100%, when presented as hemorrhagic fever. It is resistant to commonly used  
42 drugs as well as to antibiotic combinations. In-silico based functional network analysis is a key  
43 approach to get novel insights into virulence and resistance in pathogenic organisms. This study  
44 included the protein-protein interaction (PPI) network analysis of 150 specific genes identified  
45 for antibiotic resistance mechanism and virulence pathways. Eight proteins, namely, *pilL*, *fliA*,  
46 *Smlt2260*, *Smlt2267*, *cheW*, *Smlt2318*, *cheZ*, and *fliM* were identified as hub proteins. Further  
47 docking studies of selected phytochemicals were performed against the identified hub proteins.  
48 Deoxytubulosine and Corosolic acid were found to be potent inhibitors of hub proteins of  
49 pathogenic *S. maltophilia* based on protein-ligand interactive study. Further pharmacophore  
50 studies are warranted with these molecules to develop them as novel antibiotics against *S.*  
51 *maltophilia*.

52

53

54 **Keywords:** *Antimicrobial resistance, Functional network analysis, Protein-protein interaction,*  
55 *Virulence*

56

57

58

59

60

61

62

63

64

65

66 **1. INTRODUCTION**

67

68 *Stenotrophomonas maltophilia* is a waterborne aerobic Gram-negative bacterium that is rod-  
69 shaped and motile due to polar flagella. *S. maltophilia* has known to be an emerging pathogenic  
70 in immunocompromised people (Patterson et al., 2020). Exposure to this bacterium can happen  
71 both within and outside of the clinical environment (Brooke, 2012). The two most typical  
72 manifestations, bacteremia and pneumonia, have both been linked to considerable death rates  
73 during the past 20 years (Senol, 2004). Other clinical syndromes associated with this bacterium  
74 are skin and soft-tissue infections (Sakhnini et al., 2002), endocarditis, urinary tract infection,  
75 meningitis, mastoiditis, etc. (Senol, 2004).

76

77 According to estimates, there are between 5.7 and 37.7 infections for every 10,000 hospital  
78 discharges worldwide, which is considerably greater than previously thought during the years  
79 since the 1970s (Patterson et al., 2020; Said et al., 2022). The rise in immunocompromised  
80 individuals and widespread usage of broad-spectrum antibiotics are believed to be the principal  
81 causes for this growing infection rate (Said et al., 2022).

82

83 Infection management efforts are made more difficult by *S. maltophilia*'s capacity to grow  
84 biofilms on biotic surfaces and fomites. Additionally, the blurred lines between colonization  
85 and infection, and the frequent polymicrobial presentation of *S. maltophilia*, particularly in  
86 immunocompromised hosts, lead to delay in the administration of the proper antimicrobial  
87 therapy. In turn, this contributes to the overuse and abuse of antibiotics in cases of non-  
88 infection without appropriate diagnosis. Furthermore, the abundance of innate and acquired  
89 resistance mechanisms restrict the range of curative alternatives (Kullar et al., 2022).

90

91 *Stenotrophomonas* is intrinsically resistant to an assortment of antibiotics, including  
92 carbapenems, aminoglycosides, macrolides,  $\beta$ -lactams, tetracyclines, trimethoprim-  
93 sulfamethoxazole (TMP-SMX), chloramphenicol, and fluoroquinolones (Appaneal et al.,  
94 2020). Some of the most important molecular variables affecting this organism's resistance to  
95 antibiotics are the expression of qnr genes, the generation of  $\beta$ -lactamases, the presence of  
96 class 1 integrons, and efflux pumps. While most studies show that *S. maltophilia* is sensitive  
97 to TMP/SMX (Chang et al., 2015), a few studies have found resistance indicating the  
98 emergence of antimicrobial resistance (AMR) in *S. maltophilia* (Patterson et al., 2020; Saleh  
99 et al., 2021).

100

101 Given the emergence of AMR in *S. maltophilia*, drug resistance determinants are of great  
102 interest. Crossman et al. (2008) found nine potential antimicrobial efflux systems of the  
103 resistance-nodulation-division (RND) type were present, in addition to a number of genes that  
104 confer resistance to antimicrobial drugs of different sorts via other pathways.

105

106 In this work, the opportunistic pathogen *S. maltophilia* K279a was investigated using gene  
107 interaction network analysis to look into several antimicrobial resistance (AMR) and  
108 virulence genes. The exceptional ability of this specific strain to withstand drugs and heavy  
109 metals along with its pathogenicity were the reasons why it was chosen. We found  
110 biologically relevant genes involved in resistance and virulence mechanisms. Prospectively,  
111 this research will benefit wet lab researchers in designing cutting-edge therapeutic approaches  
112 to counteract *S. maltophilia* pathogenicity.

113

114

## 115 2. METHODOLOGY

116

### 117 2.1 Sequence acquisition

118 The complete genome reference sequences (RefSeqs, a total of 72) for all *S. maltophilia* were  
119 downloaded from the NCBI website (<https://www.ncbi.nlm.nih.gov/>, last accessed on Apr 27,  
120 2023). Further, sequence related metadata including the geographical origins of the isolates  
121 were also collected from the NCBI.

122

### 123 2.2 Identification of virulence and antibiotic resistance genes

124 Each genome sequence was submitted to the resistance gene identifier (RGI) tool of  
125 comprehensive antibiotic resistance database (CARD) (Alcock et al., 2020) to obtain  
126 annotations based on perfect, strict, or loose paradigm, and complete gene match criteria for  
127 the identification of antibiotic resistance genes (Rao et al., 2023). The virulence factor  
128 database (VFDB, <http://www.mgc.ac.cn/VFs/>) is a comprehensive warehouse and online  
129 platform widely used for the identification of virulence factors (VFs) (Liu et al., 2019). We  
130 used Abricate 0.9.8 (<https://github.com/tseemann/abricate>) interface to screen the VFDB  
131 using the parameters – percentage identity of  $\geq 60\%$  and coverage of  $\geq 40\%$ . The resulting  
132 lists of genes were combined and duplicate entries were removed. They were then validated  
133 by comparing against the protein-coding genes from the whole genome of *S. maltophilia*  
134 K279a strain (NC\_010943.1).

135

136 **2.3 Construction of protein-protein interaction (PPI) network**

137 In order to investigate the interacting links between the AMR and virulent genes in *S.*  
138 *maltophilia* K279a strain, they were mapped using Search Tool for the Retrieval of Interacting  
139 Genes database (STRING v.11.0, <https://string-db.org>). Visualization of the PPI network was  
140 carried out using Cytoscape (<https://cytoscape.org>). The PPI network was constructed with a  
141 high confidence level of 0.7 and then imported to Cytoscape (3.9.2) for further analysis.

142

143 **2.4 Topological analysis**

144 The PPI network was analyzed for its topological properties using Network Analyzer, a  
145 Cytoscape plugin. This tool analyses all the aspects of the PPI network. To better understand the  
146 interaction between the proteins, connectivity degree (K), betweenness centrality (BC) and  
147 closeness centrality (CC) were analyzed. These parameters provide the information about the  
148 number of proteins connected to each protein, centrality of the proteins, and the distance between  
149 them.

150

151 **2.5. Functional and pathway enrichment analysis of AMR and virulence proteins**

152 ClueGO, a Cytoscape plug-in, was used for thorough analysis and visualization of the  
153 functionally enriched set of proteins. With a p-value of  $\leq 0.05$ , STRING was used to obtain  
154 annotations and Gene Ontology (GO) concepts for genes and their functional relationships.  
155 KEGG (Kanehisa and Goto, 2000), UniProt, Pfam, and InterPro were used to comprehend  
156 critical pathway information of the genes and proteins involved in diverse activities as  
157 described in earlier study (Shetty et al., 2022).

158

159 **2.6 Screening of hub genes and clusters**

160 The PPI network was screened for its hub genes using a Cytoscape plug-in, CytoHubba (Chin et  
161 al., 2014). Top 20 genes were identified from the PPI network using each of 12 in-built  
162 algorithms of CytoHubba. The genes that overlapped in more than 6 algorithms were identified  
163 as the hub genes in the PPI network and were assumed to play a critical role in AMR and  
164 virulence. A Cytoscape plugin, Molecular Complex Detection (MCODE), with parameters set as  
165 the degree threshold (2), node score threshold (0.2), k-core threshold (4-6), and max depth of  
166 network (100) with other default parameters, was used to screen for deeply linked clusters within  
167 the PPI network. Based on the results, a suitable k-core was selected for further analysis. A  
168 subnetwork was generated with the selected nodes of the clusters from MCODE results including  
169 all edges along with seed proteins. These hub genes/proteins were considered as potential  
170 druggable targets/models, and taken for model quality assessment/evaluation and docking.

171

172 **2.7. Model quality assessment and evaluation**

173 Model validation servers were utilized to analyze the physicochemical features of the  
174 identified hub proteins and determine metrics such as Z-score, Q mean DisCo Global score,  
175 Ramachandran scores, etc. The functions of hub proteins were validated and their cellular  
176 localization was predicted to understand their function as per the methodology described  
177 earlier (Shetty et al., 2022).

178

179 **2.8. Docking studies**

180 The phytochemically derived molecules that might act as inhibitors of hub proteins based on the  
181 information that those molecules were used in the treatment of respiratory infections were  
182 selected from IMPPAT library. Docking studies with selected molecules and hub proteins were  
183 conducted to understand the chemistry of interaction. The structure of hub proteins was obtained  
184 from AlphaFold. PyRx virtual screen tool version 0.9.8 (Dallakyan and Olson, 2015) was used  
185 for the docking of the phytochemical inhibitors of hub proteins. The ligands (selected inhibitors)  
186 were retrieved from PubChem and used to create the 3D structure (Shetty et al., 2022). The  
187 ligand energy was then minimized, and a ligand file was created in accordance with the  
188 specifications. The software's requirements were followed for maintaining the docking  
189 parameter, and the optimal postures were chosen based on the binding energy. Discovery Studio  
190 2020 Client and UCSF Chimera version 1.10.1 were used to evaluate the output files.

191

192

193 **3. RESULTS**

194

195 **3.1. Reconstruction of AMR and virulence PPI network of *S. maltophilia***

196 CARD yielded 75 AMR genes while VFDB yielded 92 virulence genes (Table S1 and S2).  
197 We selected the *S. maltophilia* K279a strain because of it being the core *S. maltophilia*  
198 genome in STRING. All virulence genes were present, but only a small subset of the AMR  
199 genes (28 genes) was available in the STRING database. The network was extended by  
200 setting the total number of interactors to 50. The final network consisted of 150 genes with  
201 1479 functional interactions.

202

203 After removing the loosely bound connections, the PPI network was visualized and analyzed  
204 with Network Analyzer (Figure 1A and 1B). MCODE was used to screen the PPI network for  
205 highly interconnected clusters, which resulted in the PPI network being divided into 3 clusters

206 viz. C1 (40 nodes, 745 edges, seed protein *motA*), C2 (8 nodes, 26 edges, seed protein *Smlt2823*),  
207 C3 (16 nodes, 49 edges, seed protein *rpoA* (Figure 2). By using 12 distinct CytoHubba metrics,  
208 proteins that overlapped in 7 or more parameters were classified as top hub proteins and eight  
209 such hub proteins (*pilL*, *fliA*, *Smlt2260*, *Smlt2267*, *cheW*, *Smlt2318*, *cheZ*, and *fliM*) were  
210 identified (Table S2). These hub proteins were selected for docking analysis.

211

### 212 3.2. *Topological features of PPI network*

213 The protein interaction network (PIN) can be assessed by its mutual connections and topology.  
214 The topology of the full network and subnetwork were analyzed using Network Analyzer (Table  
215 1). The BC of the full network and subnetwork were found to be 0.0135 and 0.01857, while the  
216 CC were 0.3493 and 0.57928, respectively. The analysis revealed that the hub protein *pilL* had  
217 the highest degree value and CC value, while *Smlt2141* had high BC value (Table 2). Clustering  
218 coefficient represents the closeness of nodes and neighbors, and the hierarchical modularity of  
219 the PIN, and is used to spot the possible functional modules and uncover the molecular  
220 complexes or signaling pathways in the PIN. The clustering coefficients were 0.8097 and 0.549  
221 for the full network and subnetwork, respectively. The average number of neighbors for 150  
222 nodes was 19.7.

223

### 224 3.3. *Functional enrichment analysis*

225 Annotations and Gene Ontology (GO) terms were retrieved for the genes and their functional  
226 partners from STRING database with a p-value of  $\leq 0.05$ , where the functional enrichment  
227 analysis data of these genes were given. The data provided various properties and functions of  
228 AMR as well as virulence genes in the network. The enriched data were from KEGG  
229 pathways, Pfam protein domains, UniProt, and InterPro databases. A total of 44 GO terms  
230 were collected out of which 27, 9, and 8 terms corresponded to Biological Processes (BP),  
231 Molecular Functions (MF) and Cellular Components (CC) respectively. The top biological  
232 processes based on the number of genes associated involve cellular anatomical entity  
233 [GO:0110165], nucleotide binding [GO:0000166], purine ribonucleotide binding  
234 [GO:0032555] and cellular process [GO:0009987].

235

### 236 3.4. *Model evaluation*

237 ProtParam Tool was implemented to examine the physicochemical characteristics of *pilL*, *fliA*,  
238 *Smlt2260*, *Smlt2267*, *cheW*, *Smlt2318*, *cheZ*, and *fliM* proteins (Table 3). *CheW* showed  
239 highest aliphatic index value indicating high thermostability. The most unstable was *fliA*,  
240 which had the greatest value of the instability index, whereas *pilL* had the highest extinction

241 coefficient. The model evaluation score analysis revealed that except *pilL*, all other proteins  
242 carried a negative overall G-factor score. In *pilL*, *fliA*, *cheZ*, and *fliM*, the proportion of  
243 generously allowed regions was zero, whereas the others had values greater than zero. But the  
244 percentage of all generously allowed regions was less than 1%. The protein *Smlt2260* had a  
245 better overall quality compared to other hub proteins, as predicted by ERRAT. The Levitt-  
246 Gerstein (LG) and MaxSub scores established by ProQ, as well as the resolution estimated by  
247 ResProx, demonstrate the dependability of constructed 3D models. The Ramachandran  
248 favored percentages of the core hub proteins *pilL*, *fliA*, *Smlt2260*, *Smlt2267* and *fliM* were  
249 above 90% (Table 4) suggesting that the protein structures were of great stereochemical  
250 quality, as predicted by MOLPROBITY. The Ramachandran plot for *Smlt2260* (protein  
251 having highest percentage of favored regions) is given in Fig S1. BLASTp, MOTIF, STRING,  
252 and ScanProsite were performed to evaluate the precision of the functions annotated by  
253 GenBank. Table S7 lists the annotated functions. All hub proteins were anticipated to be  
254 localized to the cytoplasm, according to PSORTb v 3.0.3 and PSLPred, although *fliM* might  
255 have several localization sites (Table S7).

256

### 257 3.5. Docking analysis

258 Docking analysis with selected ligands (Table S8) were performed to hub proteins *pilL*, *fliA*,  
259 *Smlt2260* (*cheA*), *Smlt2267* (*cheA2*), *cheW*, *Smlt2318* (two-component response regulator  
260 chemotaxis signal), *cheZ*, and *fliM* (Table S9). The details of hydrogen bonds and the  
261 resulting binding energies for selected chosen ligands are given in Table 5. Out of multiple  
262 selected compound Deoxytubulosine showed a lower binding energies with *Smlt2267*, *cheW*,  
263 and *fliM*.

264

265 Furthermore, Corosolic acid favored to bind *Smlt2318* and *Smlt2260*, followed by Emetine to  
266 *fliA* and *pilL* proteins of *S. maltophilia*. These effective interactions of selected  
267 phytochemical-based ligands to hub proteins suggested a role in structure-activity  
268 relationship. The optimal interactions with the lowest autodock score and the best  
269 conformation are given in Figures 2, 3, and 4. Based on protein-ligand interactive study,  
270 Deoxytubulosine and Corosolic acid might be best candidate inhibitors of hub proteins of  
271 pathogenic *S. maltophilia*.

272

273

## 274 4. DISCUSSION

275

276 The continued development of antibiotics is an immediate need if humankind is to stay ahead  
277 and counter the emergence and spread of antibiotic resistance. As per recent estimates, about 0.7  
278 million deaths annually worldwide are attributed to AMR; with the number projected to grow  
279 rapidly to a tune of 10 million deaths per year by 2050 (O'Neill, 2016). Hospital infections  
280 present the most pressing need for novel therapeutics. Aside from the current AMR bacterial  
281 species, a small but increasing number of isolates, predominantly Gram-negative bacteria (such  
282 as *S. maltophilia*), are becoming resistant to previously effective antibiotics available in the  
283 market, further exacerbating the issue of antibiotic resistance (Livermore, 2004). Additionally,  
284 this bacterium has recently been identified as the most prevalent Gram-negative carbapenem-  
285 resistant pathogen isolated from clinical settings. This remains one of the relatively understudied  
286 bacteria in comparison to other Gram-negative bacteria despite having an undeniable clinical  
287 impact (Cai et al., 2020). Due to *S. maltophilia*'s inherent resistance to several antibiotics and its  
288 propensity to acquire additional resistance through horizontal gene transfer and mutation,  
289 treatment of this organism can be challenging. The strain's resistance to quinolones, cotrimoxazole,  
290 and/or cephalosporins, the antibiotics routinely used to treat *S. maltophilia* infections, have  
291 evolved in recent years (Sánchez, 2015).

292  
293 In order to maintain a steady flow of new antibacterial drug candidates into the development  
294 pipeline, it is pivotal to accelerate antibiotic optimization efforts. For this reason, it is necessary  
295 to boost the early stages of drug discovery and development since they are crucial for identifying  
296 and validating novel therapeutic candidates that can effectively combat antibacterial resistance.  
297 The attrition rate in antibacterial drug discovery has been particularly high in recent decades, as  
298 evidenced by the fact that no new class of Gram-negative antibiotics has been introduced in more  
299 than half-century (Miethke et al., 2021). However, designing entirely new scaffolds is much  
300 more expensive than developing derivatives of established compound classes (Schlander et al.,  
301 2021). Phytopharmaceuticals, which have recently attracted global interest, can be used to solve  
302 the dearth of novel medications in development (Konwar et al., 2022). Antibiotics and plant  
303 extracts work together synergistically to fight resistant bacteria, opening up new options for the  
304 treatment of infectious disorders. This feature makes it possible to continue using the specific  
305 antibiotic even after it loses its therapeutic impact (Sibanda and Okoh, 2007).

306  
307 The sequenced complete genome of *S. maltophilia* K279a was analyzed in our study. This  
308 specific strain sheds information on the potential genetic underpinnings of adaptation to various  
309 habitats, which eventually resulted in enhanced host pathogenicity and resistance to a spectrum  
310 of drugs (Abda et al., 2015). Understanding bacterial pathogenicity and their interactions with

311 the host, which may also serve as novel targets in pharmaceutical and vaccine development,  
312 requires the discovery of virulence factors. Over the past few decades, the advent of post-  
313 genomic methods, like genomics, transcriptomics, and proteomics, has sped up the discovery of  
314 virulence factors (Mason et al., 2018). We identified prospective pharmacological targets to aid  
315 in the development of innovative treatments to address the resistance mechanism.

316

317 By generating interaction networks, analyzing clusters, and investigating functional enrichment,  
318 this work revealed important information on efflux pumps and biofilm formation, as well as  
319 other drug resistance and pathogenicity mechanisms of the *S. maltophilia* K279a strain. The  
320 virulence and AMR genes found in this work have been reported previously (Huang et al., 2017).  
321 For example, the bacterial outer membrane lipoprotein *pilL* has been linked to pilus production,  
322 motility, and genetic transformation in earlier investigations (Sakai et al., 2000). *FliM* is a  
323 flagellar protein with diverse roles, while *fliA* has been demonstrated to be a sigma factor  
324 specific for class 3 flagellar operons (Eichelberg et al., 2000).

325

326 Chemotaxis is one of the known mechanisms that helps bacteria adhere to surfaces and develop  
327 by producing biofilms. This has been seen in many habitats and culture settings in various  
328 bacteria. Chemotaxis pathways would control both excitation and adaptability to environmental  
329 cues since it may be necessary for bacterial survival, metabolism, and interactions within  
330 ecological niches. *CheA* (*Smlt2260* and *Smlt2267*) is a critical gene in controlling the onset of  
331 bacterial chemotaxis. *CheA* is a methyl-accepting protein that can recognize cues from the  
332 environment (Albornoz et al., 2017). Another notable hub protein responsible for chemotaxis in  
333 our study is *cheW*, which will help us understand the genetic and biochemical makeup that will  
334 be pertinent in the search for new antibiotics (Liu et al., 1991). Another chemotactic protein,  
335 *Smlt2318*, possesses operon-like characteristics and stimulates their transcription, which may be  
336 a crucial regulatory step in the development of *S. maltophilia* biofilms (Kang et al., 2015). The  
337 hub proteins play a crucial role in the PPI network's operations. They are also implicated in a  
338 number of virulence mechanisms and may be an important source of prospective therapeutic  
339 targets (Wang et al., 2011). For experimental biologists, the network and sub-networks captured  
340 by this topological analytic technique will provide fresh perspectives on crucial regulatory  
341 networks and protein drug targets.

342

343 Both processes i.e., antimicrobial resistance and virulence mechanisms are traditionally thought  
344 to be essential for bacteria to survive in challenging environments from a biological standpoint  
345 (Christaki et al., 2020). The development of antimicrobial resistance is crucial for pathogenic

346 bacteria to be able to withstand antimicrobial therapies, overcome host defense mechanisms, and  
347 adapt to and flourish in challenging conditions. Virulence mechanisms are required to counter  
348 host defense mechanisms (Beceiro et al., 2013). Hub protein structural insights can help in the  
349 absence of phenotypic data and can also give a physical foundation for a more thorough  
350 understanding of therapeutic targets to tackle antimicrobial resistance (Shetty et al., 2022). As a  
351 result, computational methods can help with the mechanistic understanding of how different  
352 phytochemicals interact with proteins. Predicting suitable non-traditional compounds can be  
353 done by further extending our understanding of the impacts of protein-ligand stability using  
354 molecular docking experiments.

355

356 The eight hub proteins were created in this study as high-quality, energy-minimized 3D models  
357 using SWISS MODEL. On model validation servers, additional parameters and physicochemical  
358 characteristics were evaluated. The *Smlt2267* (*CheA*) protein in *Vibrio harveyi* regulate bacterial  
359 motility, and adhesion at different temperature and salinity as well as pH values. The role of  
360 *RecA* and a *CheW*-like proteins are proved to be required for surface-associated motility as well  
361 as virulence of the multi-drug resistant pathogen *Acinetobacter baumannii*. Currently, Antibiotic  
362 resistance breakers (ARBs), such as a drug combination, are being utilised to address the current  
363 issue, however alternative approaches must be introduced to combat the rise of AMR. Therefore,  
364 phytochemicals are another widely used strategy that is just as effective as other antibacterial  
365 agents. Previous studies revealed effective antibacterial and anticancer activity by  
366 deoxytubulosine which was isolated from Indian medicinal plant *Alangium lamarckii* (Rao and  
367 Venkatachalam, 1999). Moreover, corosolic acid also showed anticancer activity with limited  
368 side effects (Ma et al., 2018). Our investigation for the phytochemicals which act on *Smlt2267*,  
369 *cheW*, *fliM*, *Smlt2318*, and *Smlt2260* revealed that deoxytubulosine and corosolic acid, due to  
370 their low binding energy and high affinity, can be used as new antimicrobial agents against  
371 resistant strains of *S. maltophilia*.

372

373

## 374 CONCLUSION

375

376 We have shown protein-protein interaction network comprising 92 virulence genes and 28 AMR  
377 genes from *Stenotrophomonas maltophilia* K279a constructed and critically assessed in the  
378 current study. Eight hub proteins were identified using comparative topological analysis: *pilL*,  
379 *fliA*, *Smlt2260*, *Smlt2267*, *cheW*, *Smlt2318*, *cheZ*, and *fliM*. These proteins will contribute to the  
380 discovery of potential therapeutic targets to combat antibiotic resistance. Interestingly,

381 deoxytubulosine and corosolic acid showed better binding affinity towards *Smlt2267*, *cheW*, and  
382 *fliM*, and *Smlt2318*, and *Smlt2260*, respectively as alternative antibacterial agents for multidrug  
383 resistant *S. maltophilia*.

384

385

386 **Acknowledgments and Funding**

387 This work did not receive any specific funding, but RPS gratefully acknowledges the initial  
388 funding support from DBT, New Delhi (Grant No: BT/PR41393/MED/30/2298/2020).

389

390

391 **Statement of Ethics**

392 The work is in compliance with ethical standards. No ethical clearance was necessary.

393

394

395 **Conflict of Interest**

396 The authors declare that there is no conflict of interest.

397

398

399 **Data Availability**

400 The sequence data used in this work were obtained from NCBI. The relevant derived data are  
401 given in the supplemental tables.

402

403

404 **Author Contributions**

405 SDG, RPS, and RSPR planned the work. LP, RSPR and SDG performed the work and wrote the  
406 manuscript. SA helped in data curation. All authors contributed intellectually, and  
407 edited/reviewed the manuscript. All authors have read and agreed to the published version of the  
408 manuscript.

409

410

411 **ORCID ID**

412 Larina Pinto <https://orcid.org/0009-0006-6509-2366>

413 Rajesh P. Shastry <https://orcid.org/0000-0001-8627-9759>

414 Shivakiran Alva <https://orcid.org/0000-0003-2027-2356>

415 R. Shyama Prasad Rao <https://orcid.org/0000-0002-2285-6788>

416 Sudeep D. Ghate <https://orcid.org/0000-0001-9996-3605>

417

418

419 **Supplemental Information**

420 Supplemental information for this article is available online.

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451 **REFERENCES:**

452

453

454 Abda EM, Krysciak D, Krohn-Molt I, et al. (2015). Phenotypic heterogeneity affects  
455 *Stenotrophomonas maltophilia* K279a colony morphotypes and  $\beta$ -lactamase expression.  
456 *Frontiers in Microbiology* 6:1373.

457

458 Albornoz R, Valenzuela K, Pontigo JP, et al. (2017). Identification of chemotaxis operon  
459 *cheYZA* and *cheA* gene expression under stressful conditions in *Piscirickettsia salmonis*.  
460 *Microbial Pathogenesis* 107:436-441.

461

462 Alcock BP, Raphenya AR, Lau TTY, et al. (2020). CARD 2020: antibiotic resistome  
463 surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Research*  
464 48:517-525.

465

466 Appaneal HJ, Lopes VV, LaPlante KL, et al. (2022). Trends in *Stenotrophomonas maltophilia*  
467 antibiotic resistance rates in the United States Veterans Affairs Health System. *Journal of*  
468 *Medical Microbiology* 71:001594.

469

470 Beceiro A, Tomás M, Bou G (2013). Antimicrobial resistance and virulence: a successful or  
471 deleterious association in the bacterial world? *Clinical Microbiology Reviews* 26:185-230.

472 Brooke JS (2012). *Stenotrophomonas maltophilia*: an emerging global opportunistic pathogen.  
473 *Clinical Microbiology Reviews* 25:2-41.

474

475 Cai B, Tillotson G, Benjumea D, et al. (2020). The burden of bloodstream infections due to  
476 *Stenotrophomonas maltophilia* in the United States: A large, retrospective database study. *Open*  
477 *Forum Infectious Diseases* 7: ofaa141.

478

479 Chang YT, Lin CY, Chen YH, et al. (2015). Update on infections caused by *Stenotrophomonas*  
480 *maltophilia* with particular attention to resistance mechanisms and therapeutic options. *Frontiers*  
481 *in Microbiology* 6:893.

482

483 Chin CH, Chen SH, Wu HH, et al. (2014). CytoHubba: identifying hub objects and sub-networks  
484 from complex interactome. *BMC Systems Biology* 8:S11.

485

486 Christaki E, Marcou M, Tofarides A (2020). Antimicrobial resistance in bacteria: Mechanisms,  
487 evolution, and persistence. *Journal of Molecular Evolution* 88:26-40.

488

489 Crossman LC, Gould VC, Dow JM, et al. (2008). The complete genome, comparative and  
490 functional analysis of *Stenotrophomonas maltophilia* reveals an organism heavily shielded by  
491 drug resistance determinants. *Genome Biology* 9:R74.

492

493 Dallakyan S, Olson AJ. (2015). Small-molecule library screening by docking with PyRx.  
494 *Methods in Molecular Biology* 1263:243-250.

495

496 Denton M, Kerr KG (1998). Microbiological and clinical aspects of infection associated with  
497 *Stenotrophomonas maltophilia*. *Clinical Microbiology Reviews* 11:57-80.

498

499 Eichelberg K, Galán JE (2000). The flagellar sigma factor FliA (sigma(28)) regulates the  
500 expression of *Salmonella* genes associated with the centisome 63 type III secretion system.  
501 *Infection and Immunity* 68:2735-2743.

502

503 Huang HH, Chen WC, Lin CW, et al. (2017). Relationship of the CreBC two-component  
504 regulatory system and inner membrane protein CreD with swimming motility in  
505 *Stenotrophomonas maltophilia*. *PloS One* 12:e0174704.

506

507 Konwar AN, Hazarika SN, Bharadwaj P, et al. (2022). Emerging non-traditional approaches to  
508 combat antibiotic resistance. *Current Microbiology* 79:330.

509

510 Kullar R, Wenzler E, Alexander J, et al. (2022). Overcoming *Stenotrophomonas maltophilia*  
511 resistance for a more rational therapeutic approach. *Open Forum Infectious Diseases* 9: ofac095.

512

513 Liu B, Zheng D, Jin Q, et al. (2019). VFDB 2019: a comparative pathogenomic platform with an  
514 interactive web interface. *Nucleic Acids Research* 47: D687-D692.

515

516 Liu JD, Parkinson JS (1991). Genetic evidence for interaction between the CheW and Tsr  
517 proteins during chemoreceptor signaling by *Escherichia coli*. *Journal of Bacteriology* 173:4941-  
518 4951.

519

520 Livermore DM. (2004). The need for new antibiotics. *Clinical Microbiology and Infection: The*  
521 *Official Publication of the European Society of Clinical Microbiology and Infectious Diseases*  
522 *10:1-9.*

523

524 Ma B, Zhang H, Wang Y, et al. (2018). Corosolic acid, a natural triterpenoid, induces ER stress-  
525 dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-  
526 1/JNK, PERK/CHOP and TRIB3. *Journal of Experimental & Clinical Cancer Research* 37:210.

527

528 Mason A, Foster D, Bradley P, et al. (2018). Accuracy of different bioinformatics methods in  
529 detecting antibiotic resistance and virulence factors from *Staphylococcus aureus* whole-genome  
530 sequences. *Journal of Clinical Microbiology* 56: e01815-17.

531

532 Miethke M, Pieroni M, Weber T, et al. (2021). Towards the sustainable discovery and  
533 development of new antibiotics. *Nature Reviews Chemistry* 5: 726-749.

534

535 O'Neill J (2016). Tackling drug-resistant infections globally: final report and recommendations.  
536 Review on Antimicrobial Resistance. (<https://apo.org.au/node/63983>, last accessed on April 20,  
537 2023).

538

539 Patterson SB, Mende K, Li P, et al. (2020). *Stenotrophomonas maltophilia* infections: Clinical  
540 characteristics in a military trauma population. *Diagnostic Microbiology and Infectious Disease*  
541 *96:114953.*

542

543 Rao KN, Venkatachalam SR (1999). Dihydrofolate reductase and cell growth activity inhibition  
544 by the  $\beta$ -carboline-benzoquinolizidine plant alkaloid deoxytubulosine from *Alangium lamarckii*:  
545 Its potential as an antimicrobial and anticancer agent. *Bioorganic & Medicinal Chemistry*  
546 *7:1105-1110.*

547

548 Rao RSP, Ghate SD, Shastry RP, et al. (2023). Prevalence and heterogeneity of antibiotic  
549 resistance genes in *Orientia tsutsugamushi* and other rickettsial genomes. *Microbial Pathogenesis*  
550 *174:105953.*

551

552 Said MS, Tirthani E, Lesho E. *Stenotrophomonas maltophilia*. (2022). In: StatPearls [Internet].  
553 Treasure Island (FL): StatPearls Publishing.

554

555 Sakai D, Komano T (2000). The pilL and pilN genes of IncI1 plasmids R64 and ColIb-P9  
556 encode outer membrane lipoproteins responsible for thin pilus biogenesis. *Plasmid* 43:149-152.

557

558 Saleh RO, Hussen BM, Mubarak SMH, et al. (2021). High diversity of virulent and multidrug-  
559 resistant *Stenotrophomonas maltophilia* in Iraq. *Gene Reports* 23:101124.

560

561 Sánchez MB. (2015). Antibiotic resistance in the opportunistic pathogen *Stenotrophomonas*  
562 *maltophilia*. *Frontiers in Microbiology* 6:658.

563

564 Schlander M, Hernandez-Villafuerte K, Cheng CY, et al. (2021). How much does it cost to  
565 research and develop a new drug? A systematic review and assessment. *PharmacoEconomics*,  
566 39:1243-1269.

567

568 Senol E (2004). *Stenotrophomonas maltophilia*: the significance and role as a nosocomial  
569 pathogen. *The Journal of Hospital Infection* 57:1-7.

570

571 Shetty SP, Shastry RP, Shetty V, et al. (2022). Functional analysis of *Escherichia coli* K12 toxin-  
572 antitoxin systems as novel drug targets using a network biology approach. *Microbial*  
573 *Pathogenesis* 169:105683.

574

575 Sibanda T, Okoh AI (2007). The challenges of overcoming antibiotic resistance: Plant extracts as  
576 potential sources of antimicrobial and resistance modifying agents. *African Journal of*  
577 *Biotechnology* 6:2886-2896.

578

579 Wang J, Cao Z, Zhao, L, et al. (2011). Novel strategies for drug discovery based on Intrinsically  
580 Disordered Proteins (IDPs). *International Journal of Molecular Sciences* 12:3205-3219.

581

582

583

584

585

586

587

588

589

590 **Figure legends**

591

592 **Figure 1:** (A) Protein-protein interaction network between virulence (blue-colored) and AMR  
593 (pink-colored) nodes/proteins. Proteins categorized as both virulence and AMR are colored in  
594 yellow while extended proteins are colored in purple. Rhomboids are used to represent each of  
595 the eight hub proteins. The network has 150 nodes connected by 1479 edges. (B) Three clusters  
596 were identified (using MCODE) from the protein-protein interaction network with a MCODE  
597 score of  $>6$ . Cluster 1 (blue-colored nodes; seed protein motA, score: 32.6), Cluster 2 (green-  
598 colored nodes, seed protein Smlt2823, score: 6.0) and Cluster 3 (orange-colored nodes, seed  
599 protein rpoA, score: 5.1). Seed protein is represented in pink-colored rhomboid.

600

601 **Figure 2:** Molecular docking of FliM, CheW, and Smlt2267 with Deoxytubulosine. Binding  
602 confirmation of proteins (A, D, and G), snapshot of ligand-protein complexes (B, E, and H), and  
603 2D interactions of ligand with respective amino acids (C, F, and I) are shown.

604

605 **Figure 3:** Molecular docking of Smlt2260 and Smlt2318 with Corosolic acid. Binding  
606 confirmation of proteins (A and D), snapshot of ligand-protein complexes (B and E), and 2D  
607 interactions of ligand with respective amino acids (C and F) are shown.

608

609 **Figure 4:** Molecular docking of FliA and PiL with Emetine. Binding confirmation of proteins  
610 (A and D), snapshot of ligand-protein complexes (B and E), and 2D interactions of ligand with  
611 respective amino acids (C and F) are shown.

612

613

614

615

616

617

618

619

620

621

622

623

624 **Table 1.** MCODE parameters and topological parameters of whole network, clustered genes, and  
625 individual clusters using Network Analyzer.

Parameters	Network		Clusters		
	Whole network	Subnetwork	C1	C2	C3
Number of Nodes	150	64	40	8	16
Number of Edges	1479	829	745	26	49
Network Density	12.58	0.52	0.95	0.92	0.40
Clustering Coefficient	0.66	0.9	0.96	0.94	0.84
Average Number of Neighbors	19.72	28.67	37.25	6.5	6.12
Characteristic path length	2.99	2.05	1.04	1.07	2.01
Network Diameter	8	5	2	2	4
Betweenness centrality	0.0135	0.0185	-	-	-
Closeness centrality	0.3493	0.5792	-	-	-
Genes present in clusters			fliQ Smlt2823 rpoD		
			CheW Smlt2820 rpoA		
			motA Smlt1426 sspA		
			flhB entF clpP		
			flaA entA kdsB		
			fliL Smlt2819 tufB		
			Smlt2318 entC kdsD		
			motB Smlt2821 groEL		
			fliM lpxK		
			Smlt2306 groES		
			fliO kdsA		
			cheZ rpoZ		
			flhA htrB		
			fliC clpB		
			cheY2 dnaK		
			flgC kdtA		
			Smlt2309		
			fliI		
			Smlt2314		
			flgH		
			flgI		
			fliN		
			fliR		
			flgF		
			fliF		
			MotA		
			flgD		
			fliP		
			MotB		
			flgG		
			fliH		
			pilL		
			flhF		
			flgG		
			cheA		
			flgM		
			CheA		
			flgB		
			fliA		
			Smlt2271		

626

627

628

629

630

631

632

633

634

635 **Table 2.** List of proteins with highest betweenness centrality, closeness centrality, and degree  
636 interaction.

Protein	Betweenness centrality	Closeness centrality	Degree interaction
Smlt2141	0.206	0.476	43
pilL	0.104	0.495	74
groES	0.092	0.403	16
rpoB	0.087	0.383	12
kdsD	0.084	0.389	10
fliA	0.08	0.454	52
xanB	0.074	0.37	9
entA	0.067	0.305	9
emrB	0.066	0.325	10
PilU	0.055	0.376	15
CheA	0.051	0.482	66
entF	0.051	0.289	11
folP	0.046	0.328	8
dnaK	0.045	0.417	16
narG	0.043	0.288	5
clpB	0.04	0.382	12
CheW	0.039	0.441	48
pilM	0.033	0.369	17
acpP	0.031	0.335	4
tolC	0.031	0.271	9
clpP	0.03	0.382	13
Smlt2306	0.029	0.427	40
Smlt1037	0.028	0.377	12
flaA	0.027	0.426	39
pilT	0.025	0.363	18
emrA	0.023	0.33	7
rpoD	0.023	0.403	14
pilJ	0.022	0.425	25
fliC	0.016	0.426	44
Smlt2318	0.012	0.446	59
cheY2	0.01	0.441	55
cheR	0.007	0.432	48
flgB	0.007	0.427	43
cheB	0.006	0.427	44
cheZ	0.005	0.433	49
fliM	0.005	0.433	49
fliI	0.004	0.428	45
flgC	0.004	0.408	43
Smlt2314	0.003	0.423	41
Smlt2263	0.003	0.401	42
Smlt2309	0.003	0.42	39
flhB	0.002	0.41	47
fliG	0.001	0.408	45
fliN	0.001	0.408	45
flhA	0.001	0.408	45
fliR	0.000891	0.406	43
motB	0.000878	0.405	43
flgD	0.000765	0.406	44
flhF	0.000651	0.405	42
fliF	0.000566	0.404	41
MotA	0.000438	0.404	42
fliP	0.00041	0.403	41

637

638

639

640

641

642

643

644

645 **Table 3.** Physicochemical properties of the hub proteins.

Parameters	pilL	fliA	Smlt2260	Smlt2267	CheW	Smlt2318	cheZ	fliM
Theoretical pI	4.27	5.5	4.97	5.16	4.39	5.38	4.77	5.08
Molecular weight (kD)	237570.7	27238.8	70281.2	65129.4	17561.9	34244.2	21938.6	37673.1
Extinction coefficient	110825*	14440	30940	20065*	5960	8940	7115*	27055*
Instability index	44.49 (Unstable)	47.38 (Unstable)	40.37 (Unstable)	41.32 (Unstable)	22.24 (Stable)	44.66 (Unstable)	53.35 (Unstable)	43.34 (Unstable)
Aliphatic index	94.75	93.72	105.84	103.25	112.45	109.87	99.1	98.89
No. of amino acids	2225	247	663	609	163	314	201	334
Grand average of hydropathicity (GRAVY)	-0.176	-0.344	0.054	-0.044	0.19	0.07	-0.374	-0.149

646 \*Assuming all pairs of Cys residues form cystines.

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676 **Table 4.** Model evaluation scores of the hub proteins.

Server	Parameters	pill	fliA	Smlt2260	Smlt2267	CheW	Smlt2318	cheZ	fliM
ResProx	Predicted resolution (Å)	2.34	2.19	1.88	2.25	2.32	2.33	2.01	1.44
ERRAT	Overall quality (%)	81.5	94.1	98.7	95.6	88.4	73.9	83.1	93.4
ProSA-web	Z score	-6.37	-7.9	-8.46	-7.54	-6.72	-6.52	-3.79	-6.58
PROCHECK	Most favoured regions (%)	93.5	93.2	95.3	91.	75.7	79.3	87.2	94.2
	Additionally allowed regions (%)	6.50	6.80	3.40	6.80	22.8	18.2	10.6	5.80
	Generously allowed regions (%)	0.00	0.00	0.90	0.50	0.70	0.80	0.00	0.00
	Disallowed regions (%)	0.00	0.00	0.30	0.80	0.70	1.70	2.10	0.00
	Overall G-factor (%)	0.49	-0.05	-0.07	-0.14	-0.45	-0.51	-0.24	-0.12
	Planar groups (%), within limits)	100	91.4	92.0	93.1	92.3	85.2	96.8	85.1
SWISS-MODEL	QMEAN DisCo Global (±SD?)	0.71	0.67	0.80	0.64	0.71	0.61	0.67	0.82
		±0.06	±0.05	±0.05	±0.05	±0.07	±0.07	±0.07	±0.06
ProQ	LG score	7.129	8.675	9.693	9.735	7.124	7.283	11.466	8.827
	MaxSub	-0.304	-0.415	-0.381	-0.357	-0.326	-0.288	-0.951	-0.336
MOLPROBITY	C $\beta$ deviations >0.25Å (%)	0.00	0.93	0.59	1.01	1.39	2.27	2.00	1.80
	Residues with bad bonds (%)	0.83	0.11	0.00	0.02	0.08	0.09	0.08	0.13
	Residues with bad angles (%)	0.26	0.93	0.66	0.92	0.86	2.11	1.40	1.32
	Favoured rotamers (%)	100	91.4	97.1	89.3	88.4	92.7	92.5	96.3
	Ramachandran favoured (%)	96.7	96.1	97.1	94.4	81.2	81.3	88.9	96.1
	Ramachandran distribution Z-score (±SD?)	-1.05	1.34	1.11	0.20	-4.05	-3.23	-4.78	0.76
		±0.56	±0.56	±0.41	±0.29	±0.53	±0.63	±0.48	±0.60

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701 **Table 5.** Molecular binding affinity of selected ligands against hub proteins of *S. maltophilia*.

Protein name	Ligand	Binding affinity (kcal/mol)	Hydrogen bonds
CheW	Deoxytubulosine	-8.793	ARG108
CheZ	Cephaeline	-8.137	GLN101, ASP102
FliA	Emetine	-8.796	ARG33
FliM	Deoxytubulosine	-9.579	HIS104
PilL	Emetine	-7.988	ASP1864, ARG1871
Smlt2260	Corosolic acid	-9.174	ARG393, ASP397
Smlt2267	Deoxytubulosine	-8.648	GLN58, ASP148
Smlt2318	Corosolic acid	-8.833	HIS2, ASN21, GLU138

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

**Fig. 1.**

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023


1024

1025

1026

767

768



771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

**Fig. 2.**

790

791

792

793

794

795

796

797

798


799

800

801

802

803



804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

**Fig. 3.**

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833


834

835

836

837

838



**Fig. 4.**